| Chronic Kidney Diseases
Furoscix vs Synjardy
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Furoscix vs Synjardy with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsSynjardy has a higher rate of injection site reactions vs Furoscix based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Synjardy but not Furoscix, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Furoscix
Synjardy
At A Glance
SC injection
Loop diuretic
Oral
Once or twice daily
SGLT2 inhibitor / biguanide
Indications
- Edema
- Chronic heart failure
- Chronic Kidney Diseases
- Nephrotic Syndrome
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Congestive heart failure
- Chronic Kidney Diseases
Dosing
Edema, Chronic heart failure, Chronic Kidney Diseases, Nephrotic Syndrome 30 mg subcutaneously over the first hour followed by 12.5 mg per hour for the subsequent 4 hours (total 80 mg) via On-body Infusor applied to the abdomen; not for chronic use, replace with oral diuretics as soon as practical.
Diabetes Mellitus, Non-Insulin-Dependent SYNJARDY: empagliflozin 10 mg/day (may increase to 25 mg/day) plus metformin HCl up to 2,000 mg/day, taken orally twice daily with meals; SYNJARDY XR: once daily with morning meal; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Congestive heart failure, Chronic Kidney Diseases Empagliflozin 10 mg/day component as part of SYNJARDY or SYNJARDY XR, taken orally; not recommended if eGFR <45 mL/min/1.73 m2.
Contraindications
- Anuria
- History of hypersensitivity to furosemide, any component of the FUROSCIX formulation, or medical adhesives
- Severe renal impairment (eGFR <30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, metformin HCl, or any excipient in SYNJARDY or SYNJARDY XR
Adverse Reactions
Serious fluid, electrolyte, and metabolic abnormalities, ototoxicity, anaphylactic or anaphylactoid reactions, aplastic anemia, toxic epidermal necrolysis, Stevens-Johnson syndrome, interstitial nephritis, necrotizing angiitis
Other reported pancreatitis, jaundice, nausea, vomiting, tinnitus, hearing loss, vertigo, dizziness, headache, thrombocytopenia, agranulocytosis, leukopenia, rash, erythema multiforme, orthostatic hypotension, injection site erythema and pain, muscle spasm, restlessness
Most common (>=5%) Hypoglycemia (with sulfonylurea), urinary tract infection, nasopharyngitis, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, vitamin B12 deficiency, lower limb amputation
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, rash, urticaria, cholestatic/hepatocellular liver injury
Pharmacology
Furosemide is a loop diuretic that primarily inhibits sodium and chloride reabsorption in the proximal and distal tubules and the loop of Henle, producing high-degree diuresis independent of carbonic anhydrase inhibition or aldosterone.
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; metformin HCl is a biguanide antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Furoscix
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (5/12) · Qty limit (9/12)
Synjardy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
Furoscix
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (4/8) · Qty limit (4/8)
Synjardy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Humana
Furoscix
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (2/3) · Qty limit (0/3)
Synjardy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Furoscix.
No savings programs available for Synjardy.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
FuroscixView full Furoscix profile
SynjardyView full Synjardy profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.